Cadila Pharma Introduces Cadilose for Constipation & Liver Disorders

Cadilose is an innovative lactulose syrup developed by Cadila Pharmaceuticals, specifically designed for treating hepatic encephalopathy (HE) and constipation. 

A disaccharide-based osmotic laxative composed of galactose and fructose that promotes smooth bowel movements by maintaining intestinal water absorption while increasing water retention in the intestines and serves as a prebiotic for the growth of beneficial bacteria. Notines as a therapy agent for hepatic encephalopathy, which is a severe side effect of liver disease such as cirrhosis, and chronic constipation, ironically, it is FDA approved and established in the United States as a therapy agent for HE. Cadilose decreases the risk of colonic pH and ammonia absorption with specific dosages, promoting overall gastrointestinal health and alleviating cognitive decline associated with HE specifically. 

Cadilose contains a pleasantly flavored lemon taste to promote increased acceptability in patients while maintaining a non-habit forming and strain-free operation. The product is also sugar-free in composition, so it is suitable for individuals with any dietary restrictions to ensure compliance. 

Ultimately, cellulose will be unchanged from the initial dose to the large intestines, where colonic bacteria will metabolize it into short-chain fatty acids. The fermentation process lowers colonic pH and decreases ammonia absorption. The resulting state creates an increased osmotic pressure state additionally causes peristalsis that allows for the smooth evacuation of hardened stool and promotes water retention.

Cadilose helps treat hepatic encephalopathy by catching ammonia in the intestines and converting it into NH4 (ammonium), which the body can excrete safely. This method prevents the neurological effects of hepatic encephalopathy by significantly lowering the blood ammonia level.